The Federal Competition Commission (CFC) has announced that it is barring Nestle SA from buying Pfizer Inc’d infant formula arm in Mexico, citing competition concerns. The deal would have been made for $11.85 billion, as Nestle outbid Groupe Danone SA last April to buy the infant formula business. The CFC determined that the eventual 71 percent stake in the sector for stage one and two formula, and an 88 percent stake for stage three formula, would be too much of a dominant position for Nestle. The CFC used quantitative techniques to come to its conclusion.
Featured News
Newsom Signs Sweeping California Data Center Oversight Package
Sep 21, 2026 by
CPI
Frozen-Potato Producers Must Face Most Price-Fixing Claims, Judge Rules
Sep 21, 2026 by
CPI
Paramount Reaches Deal With States, Clearing Major Hurdle to Warner Bros. Takeover
Sep 21, 2026 by
CPI
Russia Opens Antitrust Cases Over Generic Versions of Pfizer’s Eliquis
Sep 21, 2026 by
CPI
Google Faces €403 Million EU Privacy Penalty Over Location Tracking
Sep 21, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – National Security
Sep 22, 2026 by
CPI
National Security in U.S. Antitrust Enforcement: Toward a More Disciplined Framework
Sep 22, 2026 by
Rod Rosenstein & Timothy Finley
The Department of War’s M&A Review Guidance: What Companies in the Defense Industry Need to Know
Sep 22, 2026 by
Eric Stocking & Paul Ney
National Security, Resilience and the Boundaries of Merger Control
Sep 22, 2026 by
Beatriz Marques
National Security and Competition: Building Resilient Telecommunications Networks
Sep 22, 2026 by
Roslyn Layton